Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. - Test2 - elhamkhani - TriplyDB

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.

http://www.wikidata.org/entity/Q35036388

about

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Tumor-infiltrating dendritic cells in cancer pathogenesis PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Dendritic cell-based vaccine efficacy: aiming for hot spots Targeted immune therapy of ovarian cancer Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses Breast cancer stem cells and the immune system: promotion, evasion and therapy.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Immunological landscape and immunotherapy of hepatocellular carcinoma.Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.Are peptide vaccines viable in combination with other cancer immunotherapies?Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model.Metabolic regulation of immune responses: therapeutic opportunities.Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.Molecular mechanisms involved in dendritic cell dysfunction in cancer.Progress in nonviral gene therapy for breast cancer and what comes next?What have we learned from cancer immunotherapy in the last 3 years?5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.Immunotherapy for Pediatric Brain Tumors.Cancer vaccine: learning lessons from immune checkpoint inhibitors.Association of PDCD1 gene markers with susceptibility to thyroid cancer.Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.

P2860

Q26778793-3D80F1FF-C676-47E6-ABCD-D008245F240A Q26861633-32CAFB7E-BBE1-457A-A000-369F183251E5 Q28075712-93167BCE-911E-48A9-8975-C64A10F00CF4 Q28082680-CBF9A1A2-3ADC-425E-B5EF-43594FC8CC94 Q28082828-66A32523-9D64-4296-8541-698613EAA476 Q30846001-506B1DCE-FAF1-42B5-9B33-DA38C8F792A0 Q33551626-6792DBFD-16BA-4F31-9357-86062A3D43B7 Q35853116-75BEF298-35DE-4311-915D-AC15E999A051 Q35886767-57EA13EB-445D-485D-A07E-C6E8EBED1C1B Q36173500-B94FED6C-44C1-4D6F-ABE9-A0F53ED76FD7 Q36173622-C0D35BCE-3F4A-4E21-AFB3-AB6CC9CE39B3 Q36206582-51CE38D5-5033-4A8B-95A0-12BECC76B360 Q36224057-A36DC967-40EA-4696-9706-C5F3AE4C6A98 Q36295211-F3BF37BF-CB05-43E4-98EC-D0B420F3FE42 Q36471523-A9B513AC-D985-4956-81C5-D17C3BBF14AA Q36539682-D18E06D6-708D-44F2-85E8-EED9D74CCD00 Q36582819-70D76966-4D7A-42C0-AFF2-6BBD44CC66C9 Q37010668-70D7B6E7-DB62-442C-A256-E98C2C71E857 Q38226597-24C0FAD8-BEAC-4B5A-8D10-F5D5E40BBE48 Q38600417-4C9A391D-24D0-422D-B9E6-91100BA90D95 Q38611895-3BB8C4E0-FB0F-4012-B55A-EE6010373D3D Q38643567-456D2C60-B111-4CDD-877C-483D474062EC Q38646990-EEE5C0DC-50A1-4262-AA92-61BE124FD947 Q38704573-1CC31B48-EA19-49C1-9277-156F9B383824 Q38793983-6DF0BC7F-E522-4C2C-9CF2-74702EA816BE Q38850162-6B59C5C3-CEED-4633-B9EC-1FA4BE96D1CE Q38850816-84FE72F1-D0F3-4126-9DD6-713425923A68 Q38918609-C33ABEAB-B6A3-4D43-B6D2-651144A831B4 Q39194052-47DF4138-A459-44E5-8885-721047492444 Q40065733-7EFA65B7-1F3B-44AA-970B-0BE9BA3EF46D Q40188258-F087D6A7-D1F1-4A2F-936C-DC801B54B2A9 Q41338135-25F9304E-619E-411D-98E4-82E3139BE20F Q41485890-85B26F37-4D5F-46A1-A977-4D3A13B7505F Q42695445-D6A48B41-9E53-4B95-A70B-884A7FBDB59F Q45872969-4C07225C-1955-4C86-B6DD-47DE09440A0C Q46407536-91522DC7-04CE-4A47-ABAC-11A0ECABA9E8 Q49260236-C538A283-3DC2-4E28-B4C6-08FDB72D6E9B Q51273001-89D22E8C-72F2-4761-B4FD-CF28C3500E9E Q52097229-209D7D09-637C-4649-97D5-3FA87A1BE0F7 Q52731759-A4C2CD3C-20AE-45CB-88E1-9567A8ECE608

P2860

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.

http://www.wikidata.org/entity/Q35036388

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@ast

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@en

type

label

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@ast

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@en

prefLabel

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@ast

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@en

P1433

Q35036388-932820F9-228A-43CA-8522-C92C33B14908

P1476

Q35036388-CFFADDC9-7EB8-4320-8266-80629C77BDDF

P2093

Q35036388-0550F767-AB46-48F6-9FB6-FB9ACD4DBD54

Q35036388-06E41363-06CD-4825-BC2E-C1341E593822

Q35036388-6573BF64-C483-4268-8320-05BD9BC313B7

Q35036388-732BFD95-8AE7-41ED-8E46-7572CF9012F7

Q35036388-7E81C0EC-0900-462C-AA04-4488EE42EA13

Q35036388-940C59E2-FFD6-4A3F-BD5B-BBCC119EF9C4

Q35036388-F18B0C12-535F-4C6B-B82D-5DF33FE2354D

Q35036388-F62428D9-E25E-4A47-8FD6-3A37F62330DC

P2860

Q35036388-05555592-37AC-4992-B5CD-AAFFADD554BF

Q35036388-0C7F1EE0-B6B6-40A9-AB41-86E654CDE537

Q35036388-0E34B24C-1017-4AF3-8841-47C60CA2BBFD

Q35036388-185CBBC1-DB5B-45A6-B799-8D53DD214568

Q35036388-311796DF-2C58-4FA7-83ED-85D73799F4D5

Q35036388-4550E5A0-DE1C-42EC-812B-3658F911B20D

Q35036388-5553C5C8-F4FA-461D-93CC-DE110CA1B509

Q35036388-564DF3E6-5C34-40DF-B57D-5F9728EB018F

Q35036388-58FC081C-C71E-4029-8028-A83078CB3B09

Q35036388-59A3C7D2-F773-47F0-8FB9-CA5DC3291813

P304

Q35036388-E2CE5ADF-A854-4505-8991-644FF6627B1E

P31

Q35036388-05D23511-79EF-45D4-94E0-1D19BC343D7C

P356

Q35036388-CBCCD6B6-5578-4136-A9EF-75E800166146

P407

Q35036388-BA675FBC-F870-425A-AE16-7876ACB4A9CA

P433

Q35036388-9FC76831-BCAD-4452-8541-ACBAF8C1D5F4

P478

Q35036388-10B36377-9AE1-4EA6-9B8C-F12B3815A895

P577

Q35036388-EC8FC498-8B61-4024-80E2-3CA46446A6DA

P698

Q35036388-FCED7E52-6C04-47AD-9038-B02EEBC746E5

P921

Q35036388-DDCC9DD0-BABD-44AE-BF75-4D7210FAACC2

P932

Q35036388-2E71426D-FF1E-46DA-9EE3-6A09A5A5F73B

P356

0008-5472.CAN-13-2564

P1433

Cancer Research

P1476

Accumulation of memory precurs ...... accine and anti-PD-1 antibody.

@en

P2093

Adam D Scheid

http://www.w3.org/2001/XMLSchema#string

Barath Shreeder

http://www.w3.org/2001/XMLSchema#string

James W Krempski

http://www.w3.org/2001/XMLSchema#string

Keith L Knutson

http://www.w3.org/2001/XMLSchema#string

Kimberly R Kalli

http://www.w3.org/2001/XMLSchema#string

Lavakumar Karyampudi

http://www.w3.org/2001/XMLSchema#string

Marshall D Behrens

http://www.w3.org/2001/XMLSchema#string

Purushottam Lamichhane

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant

The immunobiology of cancer immunosurveillance and immunoediting

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Immunosuppressive strategies that are mediated by tumor cells

CD27 stimulation promotes the frequency of IL-7 receptor-expressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help.

P304

2974-2985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-13-2564

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24728077

http://www.w3.org/2001/XMLSchema#string

P921

P932

4313351

http://www.w3.org/2001/XMLSchema#string